Evidence map›Paper›PMID 37937912›Full record

ArticleRevista colombiana de obstetricia y ginecologia2023

Uterine collision tumor. Case report and review of the literature

Franco Rafael Ruiz-Echeverría, María Islena Beltrán-Salazar, Lina María Caicedo-Páez, Maribel Palencia-Palacios, Catherin Salazar-Silva, David Viveros-Carreño

Abstract read
In one paragraph

Article in Revista colombiana de obstetricia y ginecologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Franco Rafael Ruiz-EcheverríaInstituto Nacional de Cancerología, Bogotá (Colombia).. est.franco.ruiz@unimilitar.edu.co.ORCID 0000-0003-2727-5840
María Islena Beltrán-SalazarInstituto Nacional de Cancerología, Bogotá (Colombia).. malebelsal@gmail.com.ORCID 0000-0003-0719-8737
Lina María Caicedo-PáezInstituto Nacional de Cancerología, Bogotá (Colombia).. lincaicedo@gmail.com.ORCID 0000-0001-7721-7994
Maribel Palencia-PalaciosInstituto Nacional de Cancerología, Bogotá (Colombia).. maribelpal@unicauca.edu.co.ORCID 0000-0003-3408-4591
Catherin Salazar-SilvaInstituto Nacional de Cancerología, Bogotá (Colombia).. est.catherin.salazar@unimilitar.edu.co.ORCID 0000-0001-8770-4753
David Viveros-CarreñoInstituto Nacional de Cancerología, Bogotá (Colombia).. dviverosc@gmail.com.ORCID 0000-0001-9395-0627

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To report the case of a patient with a uterine collision tumor and to conduct a review of the literature. Material and methods: A 76-year-old patient who presented to the national cancer referral center in Bogota (Colombia), where she was diagnosed with a uterine collision tumor consisting of a seroustype endometrial adenocarcinoma and a cervical adenosarcoma. The patient underwent surgical treatment followed by chemotherapy and supplemental radiotherapy, and died 16 months later. A search was conducted in the Medline via PubMed and Embase databases, including reports and case series of women with a diagnosis of uterine collision tumor, with retrieval of information regarding diagnosis, treatment and prognosis. A narrative summary of the findings was made. Results: The search identified 36 titles, of which 14 studies with 17 patients were included. The most frequent histopathological diagnosis was endometrial adenocarcinoma and high and low grade endometrial sarcoma (47 %). Primary treatment was surgery and adjuvant treatment with chemotherapy and radiotherapy (15 %) was performed in close to 50 % of cases. One-year survival was 75 %. Conclusions: No cases of uterine collision tumors with the histopathology or in the location of the reported case were found in the literature. If this reported case is taken into account, 2-year mortality is 28 %. Further studies to describe the immunohistochemistry, treatment and prognosis of this condition are needed.

Indexed as

AdenocarcinomaColombiaFemaleHumansendometrial neoplasmsneoplasmsuterine cervix neoplasmsUterine neoplasmsuterus

Identifiers

PMID37937912
PMCPMC10652777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.